C hronic obstructive pulmonary disease (COPD) is histologically defined by chronic airway inflammation, destruction of downstream alveoli and vasculature, and hyperinflation as air becomes trapped behind the obstructed airways. COPD affects more than 16 million Americans and is the fourth leading cause of death in the United States behind heart disease, cancer, and accidental death (1). Although COPD can result from various toxic inhalations or asthma, it is most commonly secondary to cigarette smoking (2,3). Diagnosis often relies on history of tobacco use or second-hand exposure, symptoms, and pulmonary function testing. However, it is becoming apparent that quantitative CT measurements have potential diagnostic and prognostic value (4,5), as they correlate with spirometry-based pulmonary function testing findings (6).As such, CT measurements have been included in the recently updated diagnostic criteria for COPD from the investigators of the National Institutes of Health-supported COPD Genetic Epidemiology (COPDGene) study (7).Despite the emerging use of quantitative CT, stratification of patients suspected of having COPD is currently based on spirometric pulmonary function testing findings according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (8). Analogous staging criteria with CT have not yet been defined. As diagnostic criteria begin to incorporate CT, it remains unclear how quantitative measurements might be used to establish disease severity in the clinic, and current determinations rely heavily on qualitative visual assessment (9,10). Air trapping in particular is an image